Publication of Annual Report and Notice of AGM

RNS Number : 0718O

Oxford BioDynamics PLC

25 January 2019

 

25 January 2019

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Publication of 2018 Annual Report and Accounts and Notice of AGM

Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, announces that copies of its annual report and accounts for the year ended 30 September 2018 (incorporating the Notice of Annual General Meeting) ("Annual Report") will be posted to shareholders today. An electronic copy of the Annual Report will be available on its website at www.oxfordbiodynamics.com, within the Investor Relations section.

Notice of Annual General Meeting

The Company's Annual General Meeting will be held at The Linbury Room, Worcester College, Oxford, OX1 2HB on 14 March 2019 at 11.00 am.

-ENDS-

For further details please contact:

Oxford BioDynamics Plc Christian Hoyer Millar, CEO Paul Stockdale, CFO	[phone]
Shore Capital Nominated Advisor and Broker Stephane Auton Edward Mansfield	[phone]
FTI Consulting Financial Public Relations Adviser Brett Pollard Natalie Garland-Collins	[phone]

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

 

END

 

 

DOCLFFSFLIISFIA